ID15999A - Antagonis oksitokin - Google Patents

Antagonis oksitokin

Info

Publication number
ID15999A
ID15999A IDP970772A ID970772A ID15999A ID 15999 A ID15999 A ID 15999A ID P970772 A IDP970772 A ID P970772A ID 970772 A ID970772 A ID 970772A ID 15999 A ID15999 A ID 15999A
Authority
ID
Indonesia
Prior art keywords
oxytocin antagonists
oxytocin
antagonists
Prior art date
Application number
IDP970772A
Other languages
English (en)
Indonesian (id)
Inventor
Hidenori Ogawa
Hisashi Miyamoto
Kazumi Kondo
Hiroshi Yamashita
Kenji Nakaya
Michinori Tanaka
Kazuyoshi Kitano
Keizo Kan
Michiaki Tominaga
Yoichi Yabuuchi
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of ID15999A publication Critical patent/ID15999A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IDP970772A 1992-07-02 1997-03-11 Antagonis oksitokin ID15999A (id)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP17556392 1992-07-02
JP17556692 1992-07-02

Publications (1)

Publication Number Publication Date
ID15999A true ID15999A (id) 1997-08-21

Family

ID=26496804

Family Applications (1)

Application Number Title Priority Date Filing Date
IDP970772A ID15999A (id) 1992-07-02 1997-03-11 Antagonis oksitokin

Country Status (8)

Country Link
EP (1) EP0602209A1 (enEXAMPLES)
CN (1) CN1091288A (enEXAMPLES)
AU (1) AU657424B2 (enEXAMPLES)
CA (1) CA2116334A1 (enEXAMPLES)
ID (1) ID15999A (enEXAMPLES)
MX (1) MX9304015A (enEXAMPLES)
TW (1) TW249201B (enEXAMPLES)
WO (1) WO1994001113A1 (enEXAMPLES)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356904A (en) * 1992-10-07 1994-10-18 Merck & Co., Inc. Carbostyril oxytocin receptor antagonists
GB9307527D0 (en) * 1993-04-13 1993-06-02 Fujisawa Pharmaceutical Co New venzamide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
WO1995002405A1 (en) * 1993-07-16 1995-01-26 Merck & Co., Inc. Benzoxazinone and benzopyrimidinone piperidinyl tocolytic oxytocin receptor antagonists
WO1996022775A1 (en) * 1995-01-24 1996-08-01 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
TW359669B (en) * 1995-12-15 1999-06-01 Otsuka Pharma Co Ltd Benzazepine derivatives
US5726172A (en) * 1996-01-16 1998-03-10 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
AR011913A1 (es) 1997-03-06 2000-09-13 Yamano Masaki Derivados de 4,4-difluoro-2,3,4,5-tetrahidro-1h-1-benzoazepina y composiciones farmaceuticas de los mismos.
US7326700B2 (en) 2001-04-12 2008-02-05 Wyeth Cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists
US7064120B2 (en) 2001-04-12 2006-06-20 Wyeth Tricyclic pyridyl carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists
US6900200B2 (en) 2001-04-12 2005-05-31 Wyeth Tricyclic hydroxy carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists
US7202239B2 (en) 2001-04-12 2007-04-10 Wyeth Cyclohexylphenyl carboxamides tocolytic oxytocin receptor antagonists
US7022699B2 (en) 2001-04-12 2006-04-04 Wyeth Cyclohexenyl phenyl diazepines vasopressin and oxytocin receptor modulators
US6977254B2 (en) 2001-04-12 2005-12-20 Wyeth Hydroxy cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists
US7109193B2 (en) 2001-04-12 2006-09-19 Wyeth Tricyclic diazepines tocolytic oxytocin receptor antagonists
GB0120051D0 (en) * 2001-08-16 2001-10-10 Ferring Bv Oxytocin agonists
US20050228016A1 (en) * 2002-06-13 2005-10-13 Enrique Michelotti Tetrahydroquinolines for modulating the expression of exogenous genes via an ecdysone receptor complex
CN1681487A (zh) 2002-07-15 2005-10-12 美瑞德生物工程公司 化合物、组合物及其使用方法
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
BR0315041A (pt) 2002-10-04 2005-08-16 Millennium Pharm Inc Métodos para inibir crth2 em um indivìduo que necessita inibição de crth2; composto; e composição farmacêutica
AU2003274053A1 (en) * 2002-10-22 2004-05-13 Glaxo Group Limited Aryloxyalkylamine derivates as h3 receptor ligands
TW200503994A (en) * 2003-01-24 2005-02-01 Novartis Ag Organic compounds
TWI322689B (en) 2003-02-24 2010-04-01 Otsuka Pharma Co Ltd Method for treating severe heart failure and medicament therefor
BRPI0608553A2 (pt) 2005-02-24 2010-01-12 Millennium Pharm Inc antagonistas de receptor de pgd2 para o tratamento de doenças inflamatórias
US7671058B2 (en) 2006-06-21 2010-03-02 Institute Of Medicinal Molecular Design, Inc. N-(3,4-disubstituted phenyl) salicylamide derivatives
US9096546B2 (en) 2007-05-10 2015-08-04 Albany Molecular Research, Inc. Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
TWI459947B (zh) * 2007-06-26 2014-11-11 Otsuka Pharma Co Ltd 苯并氮呯化合物及藥學製劑
CN102030709B (zh) * 2009-09-25 2013-10-16 江苏豪森医药集团有限公司 用作加压素受体拮抗剂的苯并氮杂卓类化合物
US9102669B2 (en) 2011-12-06 2015-08-11 Janssen Pharmaceutica Nv Substituted piperidinyl-pyridazinyl derivatives useful as SCD 1 inhibitors
WO2013085954A1 (en) 2011-12-06 2013-06-13 Janssen Pharmaceutica Nv Substituted piperidinyl-carboxamide derivatives useful as scd 1 inhibitors
US11690825B2 (en) 2016-03-09 2023-07-04 Board Of Regents, The University Of Texas System 20-HETE receptor (GPR75) antagonists and methods of use
WO2019003433A1 (ja) 2017-06-30 2019-01-03 大塚製薬株式会社 ベンゾアゼピン誘導体
BR112020026748A2 (pt) * 2018-06-29 2021-03-30 Kinnate Biopharma Inc. Inibidores de quinases dependentes de ciclina
US20240101568A1 (en) * 2020-11-26 2024-03-28 Shanghai Jemincare Pharmaceutical Co., Ltd Novel benzazepine spiro derivative
CN112851583B (zh) * 2021-01-19 2023-09-08 徐州医科大学 新型苯并氮杂䓬类化合物、组合物及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0382185T3 (da) * 1989-02-10 1994-07-04 Otsuka Pharma Co Ltd Carbostyrilderivater
CA2026856A1 (en) * 1989-10-05 1991-04-06 Mark G. Bock 3-substituted-1,4-benzodiazepines useful as oxytocin
ES2089033T3 (es) * 1989-10-20 1996-10-01 Otsuka Pharma Co Ltd Compuestos benzoheterociclicos.
TW199153B (enEXAMPLES) * 1990-08-07 1993-02-01 Dtsuka Seiyaku Kk

Also Published As

Publication number Publication date
CA2116334A1 (en) 1994-01-20
AU4356993A (en) 1994-01-31
AU657424B2 (en) 1995-03-09
MX9304015A (es) 1994-02-28
CN1091288A (zh) 1994-08-31
TW249201B (enEXAMPLES) 1995-06-11
WO1994001113A1 (en) 1994-01-20
EP0602209A1 (en) 1994-06-22

Similar Documents

Publication Publication Date Title
ID15999A (id) Antagonis oksitokin
FI932518A7 (fi) Angiotensiinin II antagonistit
NO932005D0 (no) Angiotensin-ii-antagonister
EP0486280A3 (en) Piperidinylcamphorsulfonyl oxytocin antagonists
DK0756868T3 (da) Aerosolpræparater
NO930543L (no) Doseringsform
FI934300A7 (fi) Bradykiniiniantagonisteja
FI932695L (fi) Angiotensin i kymas-inhibitorer inklusive humant hjaertkymas
EP0729472A4 (en) OXYTOCIN ANTAGONISTS COMPRISING PIPERIDINYLCAMPHOSULFONYL
KR950703530A (ko) 5-HT4 길항제(5-HT4 Antagonists)
FI950089A7 (fi) Dioksosyklobuteenijohdannaiset angiotensiini-II-antagonisteina
FI953009L (fi) Substituoituja 6-atsa-androstenoneja
NO952289D0 (no) Substituerte benzazepinoner
FI932544A7 (fi) Inhalator
FI945889A0 (fi) Rekombinoitu ksylanaasi
EP0708765A4 (en) PIPERAZINYLCAMPHER DERIVATIVES SUBSTITUTED AS OXYTOCIN ANTAGONISTS
FI932681L (fi) Glasoegon
ATA159592A (de) Stromrichter
FI944905A7 (fi) Endoteliiniantagonistit II
FI953646L (fi) Oksitosiiniantaginisti
DE59309389D1 (de) Substituierte Thiophencarbonsäureamide
GB9306489D0 (en) Oxytocin antagonists
EP0461707A3 (en) Peptide oxytocin antagonists
FI944307A0 (fi) Rakennusteline
DE69331261D1 (de) Hyperthermostabile beta-Galaktosidase